<a href="https://www.fiercebiotech.com/biotech/ray-therapeutics-shines-light-125m-round-targeting-genetic-eye-therapy" hreflang="en">Ray Therapeutics shines a light on $125M round targeting genetic eye therapy</a>
Ray Therapeutics has successfully closed a $125 million series B financing round to advance its gene therapy candidates for retinal degeneration, particularly targeting retinitis pigmentosa (RP). The funding, led by Janus Henderson Investors, follows the FDA granting its lead candidate, RTx-015, a Regenerative Medicine Advanced Therapy designation, highlighting the company's clinical and regulatory progress in addressing this serious condition.
Ray Therapeutics' recent $125 million series B financing, bolstered by the FDA's RMAT designation for their lead candidate RTx-015, highlights a significant investment signal in the genetic eye therapy space, particularly for treating retinitis pigmentosa. This underscores a strong momentum in gene therapy innovation and suggests potential shifts in the standard of care, making it a valuable area to watch for further developments and opportunities in healthtech and biotech investments.